title: Advances in below-the-knee drug-eluting balloons.
abstract: The management of critical limb ischemia due to below-the-knee disease remains challenging due to the frequent patient comorbidities, diffuse vascular involvement, and high rates of restenosis and disease progression. The BASIL study has established the substantial equivalence between bypass surgery and percutaneous transluminal angioplasty in this setting, at least at mid-term follow-up, but percutaneous techniques and devices have seen major developments since the publication of this pivotal trial in 2005. A major breakthrough has indeed been the introduction of drug-eluting balloons, which have several theoretical advantages in comparison to standard balloons and metallic stents for infra-popliteal lesions. Two clinical trials have already been reported with favorable results for the In.Pact Amphirion paclitaxel-eluting balloon, when employed for below-the-knee lesions. We hereby discuss the rationale for the use of drug-eluting balloons in this complex setting and the main findings of the study by Schmidt et al. and the DEBATE-BTK trial.
authors.affiliation: Cardiovascular Interventional Unit, Istituto Clinico Città Studi, Milan, Italy. robertoferraresi@fastwebnet.it
authors.forename: R
authors.initials: R
authors.lastname: Ferraresi
authors.forename: M
authors.initials: M
authors.lastname: Centola
authors.forename: G
authors.initials: G
authors.lastname: Biondi-Zoccai
mesh_terms: D000800:Angioplasty, Balloon / Q000295:instrumentation*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001157:Arterial Occlusive Diseases / Q000601:surgery*; D054855:Drug-Eluting Stents; D006801:Humans; D007866:Leg / Q000098:blood supply*; D017239:Paclitaxel / Q000494:pharmacology*; D011150:Popliteal Artery / Q000601:surgery*; D011474:Prosthesis Design; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel